TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02749747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride use
Description: 50mg sulpiride once a day use for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg placebo once a day use for 60 days
Study: NCT00240877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV024
Description: 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
Study: NCT01750853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3045697
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3045697
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3045697
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT03639610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
Study: NCT03136055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study: NCT00192491

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Sprayer of Placebo
Study: NCT04583514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Weight-stable Control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overfeeding
Description: 30% Overfeeding group
Study: NCT05072171

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair with dynamic prosthesis
Description: Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair with dynamic prosthesis
Description: Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair with dynamic prosthesis
Description: Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.

Intervention type: PROCEDURE
Intervention: Inguinal hernia repair with dynamic prosthesis
Description: Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
Study: NCT02570711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: ACP-196 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel infusion
Study: NCT03136055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01421056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day in the morning for 24 weeks
Study: NCT02570711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine infusion
Study: NCT04655859

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva cotton swab
Description: evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva cotton swab
Description: evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
Study: NCT02947958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital (control)
Description: The patient will keep his usual care at the tertiary care.
Study: NCT01742481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and empowerment
Description: Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and empowerment
Description: Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
Study: NCT03328715

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intraoperative OCT
Description: before and after surgery intraoperative OCT is performed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative OCT
Description: before and after surgery intraoperative OCT is performed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: stand-alone OCT
Description: before and after surgery stand-alone OCT is performed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stand-alone OCT
Description: before and after surgery stand-alone OCT is performed
Study: NCT01032486

Intervention type: DRUG
Intervention: Rasagiline mesylate
Description: Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
Study: NCT02743078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg every 2 weeks intravenously over 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields Therapy
Description: Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
Study: NCT01257555

Intervention type: DEVICE
Intervention: Photopneumatic therapy
Description: Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
Study: NCT01465516

Intervention type: DRUG
Intervention: Boceprevir
Description: Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results
Study: NCT04434586

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: femoropopliteal revascularization for TASC C or TASC D lesion
Description: Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoropopliteal revascularization for TASC C or TASC D lesion
Description: Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
Study: NCT02429570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclofenamate
Study: NCT02235272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: Comparison of XG-102 versus placebo sub-conjunctival injection efficacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Study: NCT02092519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle with sideport (NA-230H-8020)
Description: EUSFNA using needle with sideport

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle without sideport (NA-220H-8022)
Description: EUSFNA using needle without sideport
Study: NCT00177086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfuzosin Hydrochloride
Description: One tablet every day for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alfuzosin Hydrochloride
Description: One tablet every day for 4 weeks
Study: NCT01876394

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Shake with 50 g Coconut oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Canola Oil
Description: Shake with 50 g Canola oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Shake with 50 g Canola oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Shake with 50 g Canola oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Shake with 50 g Canola oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Shake with 50 g Canola oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil
Study: NCT01421056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 3x
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
Study: NCT00575224

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated interferon and ribavirin
Description: 180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated interferon and ribavirin
Description: 180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
Study: NCT02957630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mcg EE/150 mcg LNG
Description: 30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mcg EE/3 mg DRSP
Description: 20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study: NCT01876394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapeseed Oil
Description: Shake with 50 g Grapeseed oil
Study: NCT03270358

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling in arterioveinous fistula without stenosis
Description: Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling in arterioveinous fistula with stenosis
Description: Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
Study: NCT03516721

Intervention type: OTHER
Group type: OTHER
Intervention: the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET
Study: NCT03009864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tangshen Prescription
Description: The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangshen Prescription
Description: The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
Study: NCT03610048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: samidorphan + buprenorphine administered sublingually
Study: NCT02900430

Intervention type: OTHER
Intervention: Patients without antifungal prophylaxis
Description: Epidemiology data: clinical and biological informations collecting

Intervention type: OTHER
Intervention: Patients without antifungal prophylaxis
Description: Epidemiology data: clinical and biological informations collecting

Intervention type: DRUG
Intervention: Patients with antifungal prophylaxis
Description: Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
Study: NCT04510207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Study: NCT01876394

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chia Oil
Description: Shake with 50 g Chia oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chia Oil
Description: Shake with 50 g Chia oil
Study: NCT04510207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
Study: NCT01340456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin treatment
Description: induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin treatment
Description: induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin treatment
Description: induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
Study: NCT04033458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.
Study: NCT01876394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chia Oil
Description: Shake with 50 g Chia oil
Study: NCT04033458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participants will receive JNJ-64140284 orally.
Study: NCT01731561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Arm B)
Description: Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are \> to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (Arm A)
Description: Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
Study: NCT03009864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
Study: NCT00898846

Intervention type: DRUG
Intervention: UFT adjuvant chemotherapy
Description: UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
Study: NCT00775957

Intervention type: PROCEDURE
Intervention: FLT-PET scan
Description: imaging scan

Intervention type: PROCEDURE
Intervention: FDG-PET scan
Description: imaging scan
Study: NCT01745016

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine